New biomarkers for age-related diseases

20.03.2017 08:07

Related tags

older people at the beach

Innovative biotech company TAmiRNA has entered a partnership agreement with SimplicityBio, the Swiss-based bioinformatics company and in silico biomarker discovery specialist. TAmiRNA is a biotech company specialized in the identification and validation of biomarkers for age-related diseases such as osteoporosis, cardiovascular disease, type-2 diabetes, and cancer.

The partnership agreement signed in February 2017 aims to create compelling biomarker development services for clients from academia and biotech industry. The first objective of the partners will be to accelerate TAmiRNA´s current microRNA biomarker projects as a platform for the second step, which is to offer one-stop biomarker development services. The overall ambition is to be able to offer clients a range of advanced biomarker-based solutions for early diagnosis, prognosis, or patient stratification.

“This partnership consolidates TAmiRNA’s development pipeline and strengthens the competitive advantage of SimplicityBio´s and TAmiRNA´s biomarker development services” commented Dr. Matthias Hackl, CEO of TAmiRNA GmbH.

“This is a move of real significance for biotech and pharma companies participating in clinical studies, universities, clinical research groups and other potential partners seeking to discover and improve microRNA biomarker as well as the development and advancement of existing microRNA biomarker models to make them more sensitive, specific and robust,” added SimplicityBio co-founder and CEO, Dr. Matthew Hall.

Early diagnosis and prognosis of disease
Privately owned and headquartered in Vienna, TAmiRNA GmbH is a biotech company specialized in the identification and validation of non-coding RNAs as biomarkers for age-related diseases. The mission of TAmiRNA is to provide clinically useful biomarkers to improve and prolong patient stability, health and quality of life with increasing age.

TAmiRNA specializes in technologies for profiling levels of blood-circulating microRNAs and developing multi-parametric classification algorithms (“signatures”, also known as “models”). TAmiRNA uses these technologies to develop minimal-invasive diagnostic tests for early diagnosis and prognosis of disease, or as companion diagnostic tests to support treatment decisions.

Well filled pipeline
TAmiRNA’s pipeline includes developments in osteoporosis, cardiovascular disease, type-2 diabetes, and cancer developing ‘microRNA kit’ solutions that enable users to quantify the levels of specific microRNA combinations and platelet function in serum, plasma, urine or other biofluids. The company initially developed kits for bone disease (osteomiR) and cardiovascular disease (thrombomiR).

TAmiRNA also offers contract research services for companies in need of targeted biomarker development. Customers include (bio) pharmaceutical companies with drug development programs in human and veterinary medicine, Medtech companies and clinical research groups.

TAmiRNA was founded in November 2013 with funding boosted by investigator awards from the American Society for Bone and Mineral Research (ASBMR) and the European Calcified Tissue Society (ECTS).

(Press release)

Picture: John Boyer,

Please login or
register to comment

Please login or sign up to comment. Commenting guidelines


Apply for EC Award 2017

Application for the awards of the ETH Entrepreneurship Club is open until 27 October. Do not miss the deadline.